{"id":667618,"date":"2023-09-13T09:46:02","date_gmt":"2023-09-13T09:46:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=667618"},"modified":"2023-09-13T09:46:02","modified_gmt":"2023-09-13T09:46:02","slug":"bipolar-depression-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-abbvie-cellon-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-depression-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-abbvie-cellon-pharma_667618.html","title":{"rendered":"Bipolar Depression Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies &#8211; AbbVie, Cellon Pharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bipolar Depression Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - AbbVie, Cellon Pharma \" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Bipolar Depression Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - AbbVie, Cellon Pharma \" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s &#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>&#8221; report delivers an in-depth understanding of Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Bipolar Depression, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, and irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS); the classification is based on the characteristics of mood swings.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/08fedee71b768477c883f84e90db7cba.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Epidemiology Insights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the United States, the total number of diagnosed Bipolar Depression prevalent cases was 2,401,287 cases in the year 2020.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In the year 2020, the total diagnosed Bipolar Depression prevalent cases were 1,004,168 cases in EU-5.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">In Japan, the total number of diagnosed Bipolar Depression prevalent cases was 146,621 cases in the year 2020.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Bipolar Depression Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<strong>The Report Covers the Bipolar Depression Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression treatment cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bipolar Depression diagnosed cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market trends by analyzing the impact of current Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder therapies on the market, unmet needs, drivers and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">This segment gives a thorough detail of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder market in 7MM is expected to witness a major change in the study period 2019-2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the Bipolar Depression Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intra-Cellular Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NeuroRx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sunovion (Sumitomo Dainippon Pharma)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lundbeck\/Otsuka Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Celon Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">COMPASS Pathways<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AbbVie<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Therapies Covered and Analyzed in the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Brexpiprazole<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;OSU6162<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Vortioxetine<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Valprote<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Olanzapine<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-market\">Key Companies and Emerging Therapies in the Bipolar Depression Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Bipolar Depression Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Executive Summary of Bipolar Depression&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Bipolar Depression Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Bipolar Depression Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn about the detailed offerings of the report @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-disorder-manic-depression-market\">Bipolar Depression Market Outlook<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bipolar-depression-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-abbvie-cellon-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bipolar-depression-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-abbvie-cellon-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-depression-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-key-companies-abbvie-cellon-pharma_667618.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-667618","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=667618"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/667618\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=667618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=667618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=667618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}